Immunomodulatory Type II Natural Killer T Lymphocytes in Health and Disease

Scandinavian Journal of Immunology

Volumn 76, Issue 3, 2012, Pages 246-255

  Rhost, S ^a   Sedimbi, S ^a   Kadri, N ^b   Cardell, S L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CELL FUNCTION; GRAFT VERSUS HOST REACTION; HEPATITIS; HUMAN; IMMUNE FUNCTION TEST; IMMUNITY; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NATURAL KILLER T CELL; NATURAL KILLER T CELL TYPE 2; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; ULCERATIVE COLITIS;

ANIMALS; HUMANS; KILLER CELLS, NATURAL; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS;

EID: 84865399909     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02750.x     Document Type: Review

References (76)

1. Cardell S, Tangri S, Chan S, Kronenberg M, Benoist C, Mathis D. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J Exp Med 1995;182:993-1004.
2. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863-5.
3. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-7.
4. Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J Exp Med 1994;180:1171-6.
5. Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med 1993;178:1-16.
6. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
7. Kadri N, Blomqvist M, Cardell SL. Type II natural killer T cells: a new target for immunomodulation? Expert Rev Clin Immunol 2008;4:615-27.
8. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res 2008;101:277-348.
9. Arrenberg P, Halder R, Kumar V. Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. J Cell Physiol 2009;218:246-50.
10. Colgan SP, Hershberg RM, Furuta GT, Blumberg RS. Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical role of the cytoplasmic tail in autocrine signaling. Proc Natl Acad Sci USA 1999;96:13938-43.
11. Yue SC, Shaulov A, Wang R, Balk SP, Exley MA. CD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12. Proc Natl Acad Sci USA 2005;102:11811-6.
12. Teng MW, Yue S, Sharkey J, Exley MA, Smyth MJ. CD1d activation and blockade: a new antitumor strategy. J Immunol 2009;182:3366-71.
13. Berzofsky JA, Terabe M. The contrasting roles of NKT cells in tumor immunity. Curr Mol Med 2009;9:667-72.
14. Fuss IJ, Heller F, Boirivant M et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7.
15. Exley MA, Tahir SM, Cheng O et al. A major fraction of human bone marrow lymphocytes are Th2-like CD1d- reactive T cells that can suppress mixed lymphocyte responses. J Immunol 2001;167:5531-4.
16. Exley MA, He Q, Cheng O et al. Cutting edge: compartmentalization of Th1-like noninvariant CD1d- reactive T cells in hepatitis C virus-infected liver. J Immunol 2002;168:1519-23.
17. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004;199:947-57 [Epub 2004 Mar 29].
18. Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G. Self glycolipids as T-cell autoantigens. Eur J Immunol 1999;29:1667-75.
19. Brandl C, Ortler S, Herrmann T, Cardell S, Lutz MB, Wiendl H. B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells. PLoS One 2010;5:e10800.
20. Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010;10:501-13.
21. Skold M, Faizunnessa NN, Wang CR, Cardell S. CD1d-specific NK1.1+ T cells with a transgenic variant TCR. J Immunol 2000;165:168-74.
22. Duarte N, Stenstrom M, Campino S et al. Prevention of diabetes in non obese diabetic (NOD) mice mediated by non-classical NKT cells. J Immunol 2004;173:3112-8.
23. Kadri N, Korpos E, Gupta S et al. CD4+ type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. J Immunol 2012;188:3138-49.
24. Andersson K, Buschard K, Fredman P et al. Patients with insulin-dependent diabetes but not those with non-insulin-dependent diabetes have anti-sulfatide antibodies as determined with a new ELISA assay. Autoimmunity 2002;35:463-8.
25. Subramanian L, Blumenfeld H, Tohn R et al. NKT cells stimulated by long fatty acyl chain sulfatides significantly reduces the incidence of type 1 diabetes in nonobese diabetic mice. PLoS One 2012;7:e37771.
26. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-38.
27. Liao CM, Zimmer MI, Shanmuganad S, Yu HT, Cardell SL, Wang CR. Dysregulation of CD1d-restricted type ii natural killer T cells leads to spontaneous development of colitis in mice. Gastroenterology 2012;142:326-34.e1-2.
28. Kim JH, Choi EY, Chung DH. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4. J Immunol 2007;179:6579-87.
29. Pillai AB, George TI, Dutt S, Teo P, Strober S. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 2007;178:6242-51.
30. Shaulov A, Yue S, Wang R et al. Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival. Exp Hematol 2008;36:464-72.
31. Satoh M, Andoh Y, Clingan CS et al. Type II NKT cells stimulate diet-induced obesity by mediating adipose tissue inflammation, steatohepatitis and insulin resistance. PLoS One 2012;7:e30568.
32. Durante-Mangoni E, Wang R, Shaulov A et al. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol 2004;173:2159-66.
33. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002;16:583-94.
34. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 2007;117:2302-12.
35. Kronenberg M, Kinjo Y. Innate-like recognition of microbes by invariant natural killer T cells. Curr Opin Immunol 2009;21:391-6.
36. Brigl M, Brenner MB. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Semin Immunol 2010;22:79-86.
37. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun 2005;73:181-92.
38. Mallevaey T, Zanetta JP, Faveeuw C et al. Activation of invariant NKT cells by the helminth parasite Schistosoma mansoni. J Immunol 2006;176:2476-85.
39. Kawano T, Cui J, Koezuka Y et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 1998;95:5690-3.
40. Sfondrini L, Besusso D, Zoia MT et al. Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice. J Immunol 2002;169:151-8.
41. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 2008;111:5637-45.
42. Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One 2011;6:e20702.
43. Chang DH, Deng H, Matthews P et al. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood 2008;112:1308-16.
44. Zhou D, Mattner J, Cantu C 3rd et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306:1786-9.
45. Brennan PJ, Tatituri RV, Brigl M et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat Immunol 2011;12:1202-11.
46. Facciotti F, Ramanjaneyulu GS, Lepore M et al. Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus. Nat Immunol 2012;13:474-80.
47. Zajonc DM, Kronenberg M. Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells. Immunol Rev 2009;230:188-200.
48. Makowska A, Kawano T, Taniguchi M, Cardell S. Differences in the ligand specificity between CD1d-restricted T cells with limited and diverse T-cell receptor repertoire. Scand J Immunol 2000;52:71-9.
49. Gumperz JE, Roy C, Makowska A et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000;12:211-21.
50. Roark JH, Park SH, Jayawardena J, Kavita U, Shannon M, Bendelac A. CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells. J Immunol 1998;160:3121-7.
51. Brossay L, Tangri S, Bix M, Cardell S, Locksley R, Kronenberg M. Mouse CD1-autoreactive T cells have diverse patterns of reactivity to CD1+ targets. J Immunol 1998;160:3681-8.
52. Chiu YH, Jayawardena J, Weiss A et al. Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J Exp Med 1999;189:103-10.
53. Roberts TJ, Sriram V, Spence PM et al. Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J Immunol 2002;168:5409-14.
54. Salio M, Speak AO, Shepherd D et al. Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc Natl Acad Sci USA 2007;104:20490-5.
55. Paget C, Mallevaey T, Speak AO et al. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity 2007;27:597-609.
56. Darmoise A, Teneberg S, Bouzonville L et al. Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity 2010;33:216-28.
57. Berntman E, Rolf J, Johansson C, Anderson P, Cardell SL. The role of CD1d-restricted NK T lymphocytes in the immune response to oral infection with Salmonella typhimurium. Eur J Immunol 2005;35:2100-9.
58. Wesley JD, Tessmer MS, Chaukos D, Brossay L. NK cell-like behavior of Valpha14i NK T cells during MCMV infection. PLoS Pathog 2008;4:e1000106.
59. Brigl M, Tatituri RV, Watts GF et al. Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J Exp Med 2011;208:1163-77.
60. Wang X, Bishop KA, Hegde S, Rodenkirch LA, Pike JW, Gumperz JE. Human invariant natural killer T cells acquire transient innate responsiveness via histone H4 acetylation induced by weak TCR stimulation. J Exp Med 2012;209:987-1000.
61. Behar SM, Podrebarac TA, Roy CJ, Wang CR, Brenner MB. Diverse TCRs recognize murine CD1. J Immunol 1999;162:161-7.
62. Arrenberg P, Halder R, Dai Y, Maricic I, Kumar V. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc Natl Acad Sci USA 2010;107:10984-9.
63. Ambrosino E, Terabe M, Halder RC et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 2007;179:5126-36.
64. Blomqvist M, Rhost S, Teneberg S et al. Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur J Immunol 2009;39:1726-35.
65. Jeon SB, Yoon HJ, Park SH, Kim IH, Park EJ. Sulfatide, a major lipid component of myelin sheath, activates inflammatory responses as an endogenous stimulator in brain-resident immune cells. J Immunol 2008;181:8077-87.
66. Nofer JR, Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 2005;15:265-71.
67. Rhost S, Löfbom L, Rynmark B-M, Pei B, Månsson J-E, Teneberg S, Blomqvist M and Cardell SL. Identification of novel glycolipid ligands activating a sulfatide reactive, CD1d-restricted, type II natural killer T (NKT) lymphocyte. Eur J Immunol DOI: 10.1002/eji.201142350.
68. Mori L, De Libero G. T cells specific for lipid antigens. Immunol Res 2012; [Epub ahead of print].
69. Pellicci DG, Clarke AJ, Patel O et al. Recognition of beta-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat Immunol 2011;12:827-33.
70. Zajonc DM, Maricic I, Wu D et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med 2005;202:1517-26.
71. Park SH, Weiss A, Benlagha K, Kyin T, Teyton L, Bendelac A. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 2001;193:893-904.
72. Uldrich AP, Patel O, Cameron G et al. A semi-invariant Valpha10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. Nat Immunol 2011;12:616-23.
73. Brigl M, van den Elzen P, Chen X et al. Conserved and heterogeneous lipid antigen specificities of CD1d-restricted NKT cell receptors. J Immunol 2006;176:3625-34.
74. Gadola SD, Dulphy N, Salio M, Cerundolo V. Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes. J Immunol 2002;168:5514-20.
75. Agea E, Russano A, Bistoni O et al. Human CD1-restricted T cell recognition of lipids from pollens. J Exp Med 2005;202:295-308.
76. Van Rhijn I, Young DC, Im JS et al. CD1d-restricted T cell activation by nonlipidic small molecules. Proc Natl Acad Sci USA 2004;101:13578-83.